Stock Ratings / Health Care / EVMN / earnings

ELDN (49) LFCR (51) VNDA (37) CAMP (34) ⌘ Pro Terminal →

Evommune Inc. (EVMN) Next Earnings Date & Expected ±12.5% Move

$6.81 +7.92% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Evommune Inc. (EVMN) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $247.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVMN)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.85 Expected Swing

MODEL EARNINGS SETUP GAUGE

EVMN Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 85.7%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$13.0M	-$68.9M	-$76.7M	52%
FY 2024	2024-12-31	$7.0M	-$66.8M	-$58.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVMN)

✓Walkthrough of EVMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EVMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.39%▲ RESISTANCE BREAKOUT

2026-10-30O $6.65H $6.84L $6.29C $6.81VOL 586.4K

RES: $6.78SUP: $4.51SMA50: $8.79SMA200: $17.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EVMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EVMN Butterfly Map → + Track EVMN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +85.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EVMN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EVMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EVMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVMN)

Health Care Rank #548 of 1016 ⚔️ ELDN vs EVMN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EVMN vs. ELDN, LFCR, VNDA, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Evommune Inc. (EVMN) ranks #548 by composite RQD confidence (43/100, grade D-) and #548 by equity capitalization ($247.1M). Within this direct 5-issuer industry benchmark cohort, EVMN leads on earnings valuation at N/A trailing P/E, while EVMN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with EVMN at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EVMN ACTIVE Evommune Inc.	D-	43/100	—	—	-35.0%	+7.92%	$247.1M	Benchmark Subject
ELDN Eledon Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+10.15%	$247.0M	/eldn-vs-evmn →
LFCR Lifecore Biomedical Inc.	D	51/100	—	—	—	+0.15%	$246.8M	/lfcr-vs-evmn →
VNDA Vanda Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+1.25%	$244.9M	/vnda-vs-evmn →
CAMP CAMP4 Therapeutics Corporation	E	34/100	—	—	-35.0%	+6.85%	$244.7M	/camp-vs-evmn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002044725

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Evommune Inc. (EVMN) reported GAAP revenue of $13.0M (+85.7% vs. FY2024 revenue of $7.0M ) , GAAP net income of -$68.9M, operating cash flow of -$76.4M, and free cash flow of -$76.7M (-31.6% YoY). On the balance sheet, EVMN closed FY2025 with $224.9M in total assets against $0 in total debt (Altman Z-Score: 5.87, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.0M	-$68.9M	-$76.4M	-$76.7M	$224.9M	—
FY2024 (FY)	2024-12-31	$7.0M	-$66.8M	-$58.2M	-$58.3M	$76.1M	—

3. EVMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EVMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Evommune Inc. (NYSE: EVMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $6.81 (+7.92% 1D, market cap $247.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EVMN ranks #548 in composite RQD confidence.

How does EVMN compare to ELDN and LFCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVMN carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELDN (Eledon Pharmaceuticals Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $247.0M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, EVMN leads on earnings multiple (N/A) while EVMN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EVMN?

Per EVMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002044725), Evommune Inc. generated $13.0M in revenue (+85.7% YoY), -$68.9M in net income, and -$76.7M in free cash flow against $224.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EVMN trading relative to its 50-day, 200-day, and 52-week technical levels?

EVMN last traded at $6.81 (+7.92% on volume of 1,154,881 shares), positioning the stock -22.53% below its 50-day simple moving average ($8.79) and -61.66% below its 200-day simple moving average ($17.76). Across its 52-week range of $4.94 to $33.20, EVMN sits at the 6.6% percentile with a 14-day RSI of 49.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.96 to $7.66).